Having been working in the neurodegeneration space, in May 2013, Satori Pharmaceuticals, Inc. Ceased operations. The firm had operated as a biopharmaceutical company developing new kinds of drugs to treat protein misfolding diseases, including Alzheimer's disease and Parkinson's disease, and type 2 diabetes. The company had also developed a portfolio of preclinical programs that provide a drug development pipeline